Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of a Plant-derived Quadrivalent VLP Influenza Vaccine in Adults ≥65 Years
2018-001894-26Phase 3Completed
- Sponsor
- Medicago Inc.
- Start
- Jul 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of plant-derived quadrivalent influenza virus-like particle vaccine in seasonal influenza and influenza (2 arms), sponsored by Medicago Inc. Primary endpoint: Vaccine efficacy against protocol-defined influenza-like illness. Started Jul 2018; status: completed.
02
Drugs
plant-derived quadrivalent influenza virus-like particle vaccine
03
Conditions
seasonal influenzainfluenza
Beyond the preview
Go deeper on 2018-001894-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001894-26.